A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG
Key facts
- Where
- Sacramento, United StatesSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with suspected prostate cancer spread or with suspected or diagnosed somatostatin receptor positive neuroendocrine tumors. They will have research PET scans on a total-body scanner.
- Age
- Older than 18 years
- Sex
- All sexes can join.
- Disease stage
- Suspected prostate cancer metastasis, or suspected or diagnosed somatostatin receptor positive neuroendocrine tumors (NETs).
- Earlier treatment
- People who recently had long-acting somatostatin analogs cannot join the neuroendocrine tumor group.
- Biomarker or test result
- Neuroendocrine tumors must be somatostatin receptor positive. Earlier scans must look suspicious: for prostate cancer, a CT, MRI, bone scan and/or Fluciclovine scan within 4 months of the research scan. For neuroendocrine tumors, a DOTATATE PET/CT scan.
Main reasons for not taking part
- Adults who cannot give consent
- Pregnant or breastfeeding people
- Prisoners
- Cannot lie flat on the back for up to 90 minutes
- Uncontrolled claustrophobia (fear of closed spaces)
Read by machine on 9 November 2026.
Where in United States
- UC Davis EXPLORER Molecular Imaging CenterSacramento, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of California, Davis
- Trial code
- NCT05160480
- Record updated
- 27 October 2026
- Original description
The purpose of this research study is to test new ways to improve the usefulness of the world's first total-body positron emission tomography (PET)/computed tomography (CT) scanner (EXPLORER) by collecting data from PET scans using one of three different imaging agents: 18F-PSMA; 18F-FES; or, 68Ga DOTATATE. These imaging agents are approved by the FDA to be used for patients diagnosed with prostate cancer (18F-PSMA), neuroendocrine tumor (68Ga DOTATATE), or breast cancer (18F-FES).Read full original descriptionShow less
The purpose of this research study is to test new ways to improve the usefulness of the world's first total-body positron emission tomography (PET)/computed tomography (CT) scanner (EXPLORER) by collecting data from PET scans using one of three different imaging agents: 18F-PSMA; 18F-FES; or, 68Ga DOTATATE. These imaging agents are approved by the FDA to be used for patients diagnosed with prostate cancer (18F-PSMA), neuroendocrine tumor (68Ga DOTATATE), or breast cancer (18F-FES).
Inclusion: Persons >18 yo with suspected prostate cancer metastasis; Prior imaging study (CT, and/or MRI and/or Bone scan and/or Fluciclovine scan) suspicious for metastatic disease, obtained within 4 months from the research scan date; 68Ga DOTATATE (n=3) or 64Cu-DOTATATE (n=3); Persons > 18 yo suspicious for or diagnosed with somatostatin receptor positive neuroendocrine tumors (NETs); Prior DOTATATE PET/CT scan suspicious for tumor obtained not earlier than 4 months from the research scan date.
Exclusion: Any significant medical condition that in the opinion of the investigator would prevent the participant from participating and/or adhering to study related procedures or interfere with participant safety; Recent administration of long-acting somatostatin analogs; Adults unable to consent; Pregnant/lactating persons; Prisoners; Unable to lie supine for up to 90 minutes at different timepoints in the PET scanner; Uncontrolled claustrophobia.
18F-PSMA (n=3) and 68Ga-PSMA (n=3).